Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lithium carbonate
Drug ID BADD_D01303
Description Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Indications and Usage Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder[FDA Label].
Marketing Status approved
ATC Code Not Available
DrugBank ID DB14509
KEGG ID D00801
MeSH ID D016651
PubChem ID 11125
TTD Drug ID D04UUH
NDC Product Code 31722-546; 62332-148; 62756-430; 63187-304; 64980-205; 68462-221; 70518-0608; 70518-2312; 70518-2345; 70518-3565; 72789-171; 72789-172; 31722-544; 62332-014; 68071-2714; 0054-8531; 46708-303; 55154-4920; 63629-1916; 0378-1450; 70518-0668; 70518-3681; 0054-4527; 62332-013; 68462-220; 68462-222; 68462-223; 70518-0437; 70518-2699; 68084-655; 70518-1434; 0054-2531; 71335-0120; 0054-8528; 0615-8302; 50090-3917; 58118-0545; 0054-8526; 51079-142; 63629-1917; 68462-224; 71610-557; 72789-173; 39345-5104; 46708-305; 0378-1300; 64980-278; 70518-1753; 70518-2086; 0054-2526; 31722-545; 50090-1470; 62332-015; 62559-280; 0054-0020; 68428-481; 0054-2527; 72789-174; 82388-001; 46708-148; 50090-6052; 64117-256; 0054-0021; 68084-640; 70518-0904; 70518-1481; 0054-8527; 66039-947; 73309-248; 23155-763; 42291-496; 43063-901; 46708-304; 51079-180
UNII 2BMD2GNA4V
Synonyms Lithium Carbonate | Carbonate, Lithium | Dilithium Carbonate | Carbonate, Dilithium | Lithane | Lithium Bicarbonate | Bicarbonate, Lithium | Lithobid | Lithonate | CP-15,467-61 | CP 15,467 61 | CP15,46761 | Micalith | NSC-16895 | NSC 16895 | NSC16895 | Priadel | Quilinorm-retard | Quilinorm retard | Quilinormretard | Eskalith | Lithotabs
Chemical Information
Molecular Formula CLi2O3
CAS Registry Number 554-13-2
SMILES [Li+].[Li+].C(=O)([O-])[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Memory impairment17.03.02.003; 19.20.01.003--
Mental disability26.01.01.001---
Mental impairment17.03.03.002; 19.21.02.0030.000535%-
Metabolic acidosis14.01.01.0030.001606%-
Mood swings19.04.03.0010.000535%-
Mucosal dryness08.01.06.0010.000535%-
Muscle contractions involuntary15.05.03.008; 17.05.03.001---
Muscle rigidity15.05.04.001; 17.05.02.0050.000803%-
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005---
Muscular weakness15.05.06.001; 17.05.03.0050.001071%
Myasthenia gravis10.04.05.001; 15.05.08.001; 17.05.04.001--
Myocarditis02.04.03.0010.000535%
Myoclonus17.02.05.0080.003587%-
Myxoedema05.02.03.002; 23.07.04.007---
Nail discolouration23.02.05.001--
Nausea07.01.07.001--
Neoplasm malignant16.16.01.0010.000535%-
Nephrogenic diabetes insipidus14.05.07.002; 20.05.03.0100.010654%-
Nephrolithiasis20.04.01.0020.000535%
Nephropathy20.05.03.0010.008298%-
Nephropathy toxic12.03.01.010; 20.05.03.0020.004551%-
Nervous system disorder17.02.10.0010.001606%-
Neuroleptic malignant syndrome08.05.01.005; 12.03.01.003; 15.05.04.015; 17.05.02.0030.000535%-
Neurotoxicity12.03.01.011; 17.02.10.0020.003748%-
Nodal rhythm02.03.03.0210.000535%-
Nystagmus06.05.02.006; 17.02.02.0060.000803%
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oliguria20.01.03.004---
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene